Your Patient Needs Lokelma — Here's How to Help Them Get It

You've prescribed Lokelma (Sodium Zirconium Cyclosilicate) because it's the right medication for your patient's hyperkalemia. But then the phone rings: "My pharmacy says they don't have it." Or worse, the patient simply goes without — and their next lab shows potassium climbing back to dangerous levels.

This guide provides a practical, step-by-step approach to helping your patients find and maintain access to Lokelma. Whether you're in nephrology, cardiology, or primary care, these strategies can be integrated into your existing prescribing workflow.

Current Availability: What You Need to Know

Lokelma is not in formal shortage as of 2026. AstraZeneca maintains production, and the drug is available through standard pharmaceutical distribution channels. The challenge is at the last mile:

• Most retail pharmacies don't stock Lokelma routinely. As a specialty medication with a relatively narrow patient population, it's not a standard shelf item at chain pharmacies.
• No generic exists. AstraZeneca is the sole manufacturer, so there's no competition to ensure redundant supply.
• It comes in a unique dosage form — powder for oral suspension in 5g and 10g foil packets — that's unfamiliar to some pharmacy staff.

For a complete overview of the current supply situation, see our Lokelma shortage briefing for providers.

Why Patients Can't Find Lokelma

Understanding the common barriers helps you anticipate and address them proactively:

Pharmacy Stocking

Chain pharmacies like CVS, Walgreens, and Rite Aid generally stock based on demand algorithms. If a location hasn't filled many Lokelma prescriptions recently, the system won't flag it for routine ordering. The pharmacy can order it — they just don't keep it.

Insurance Barriers

Lokelma sits on Tier 4 (specialty) on most formularies. Patients frequently encounter:

• Prior authorization: Delays of 2-7 days while the PA is processed
• Step therapy: Insurer requires trial of Kayexalate (SPS) before covering Lokelma
• High copays: Even with coverage, specialty-tier cost-sharing can be $100-$200+/month

Geographic Gaps

Patients in rural areas or regions with fewer specialty pharmacies face compounded access challenges. Their local pharmacy may not have a wholesaler relationship that includes Lokelma in regular shipments.

Patient Awareness

Many patients don't know they have options beyond their usual pharmacy. They assume "not in stock" means "not available," and may delay or abandon treatment without communicating the issue to your office.

What Providers Can Do: 5 Practical Steps

Step 1: Direct Patients to the Right Pharmacy

The single most impactful thing you can do is steer patients toward pharmacies that actually stock Lokelma. Use Medfinder for Providers to identify pharmacies with current inventory near your patient's location.

Build a short list of 2-3 reliable pharmacies for Lokelma in your area and share it proactively with patients at the time of prescribing. This prevents the frustrating cycle of patients calling multiple pharmacies on their own.

Step 2: Prescribe Proactively

Don't wait until the patient runs out of their current therapy to write the Lokelma prescription. Plan ahead:

• Write the prescription at least 7-10 days before the patient will need it
• If starting a new patient, consider whether you have samples to bridge the gap while the pharmacy orders the medication
• Specify the pharmacy on the prescription if you know which one stocks it — this avoids the default routing to a chain pharmacy that doesn't carry it

Step 3: Streamline Prior Authorization

If your patient's insurance requires PA, submit it proactively — ideally at the same time you write the prescription, not after the pharmacy sends back a rejection.

Key documentation to include in PA requests:

• Confirmed hyperkalemia diagnosis with recent serum potassium levels
• Clinical rationale for Lokelma over Kayexalate (e.g., better GI safety profile, need for chronic therapy, maintaining RAAS inhibitor therapy)
• Any prior intolerance or contraindication to alternative agents
• Comorbidities that support Lokelma use (CKD, heart failure, chronic RAAS inhibitor therapy)

If step therapy is required, document any trial of Kayexalate/SPS and the reason it was discontinued or inadequate.

Step 4: Connect Patients With Financial Support

Cost is often the silent reason patients don't fill their prescriptions. Proactively inform patients about:

• AstraZeneca Co-pay Savings Card: Eligible commercially insured patients may pay as little as $0/month
• AZ&Me Patient Assistance Program: Free medication for qualifying uninsured/underinsured patients
• My Access 360: AstraZeneca's comprehensive support hub at myaccess360.com — handles benefits verification, PA support, copay assistance, and patient assistance enrollment

Consider having your office staff incorporate My Access 360 enrollment into the prescribing workflow for all new Lokelma patients. For detailed cost information to share with patients, see our guide on saving money on Lokelma.

Step 5: Establish a Follow-Up Protocol

Don't assume the patient successfully filled the prescription. Build in a check:

• Have your staff follow up with the patient 3-5 days after prescribing to confirm the prescription was filled
• If using a specialty pharmacy, they often provide adherence tracking and can alert your office to fill issues
• Monitor serum potassium levels per standard of care — persistently elevated levels may indicate non-adherence due to access issues

Alternatives: When to Consider a Switch

If Lokelma access proves consistently problematic for a patient, the primary alternatives are:

Veltassa (Patiromer)

• Comparable efficacy for chronic hyperkalemia management
• Different mechanism: binds potassium in exchange for calcium (vs. hydrogen/sodium for Lokelma)
• Slower onset: 4-7 hours vs. ~1 hour for Lokelma
• Requires 3-hour separation from other oral medications (vs. 2 hours for Lokelma)
• Similar price point: $800-$1,200/month without insurance
• May be covered differently by the patient's plan — worth checking if Lokelma is denied

Kayexalate (Sodium Polystyrene Sulfonate)

• Widely available, generic, and inexpensive ($20-$60/month)
• Higher GI side effect burden; rare risk of intestinal necrosis (especially with sorbitol)
• Less selective potassium binding — monitor calcium and magnesium
• Reasonable short-term bridge; less ideal for long-term chronic management

Non-Pharmacologic Approaches

• Dietary potassium restriction (adjunctive, rarely sufficient alone for moderate-severe hyperkalemia)
• RAAS inhibitor dose adjustment (may compromise cardiovascular/renal protection)
• Loop diuretic addition (promotes urinary potassium excretion)
• Dialysis optimization (for ESKD patients)

For a patient-facing comparison, share our article on alternatives to Lokelma.

Workflow Tips for Your Practice

Here are practical ways to integrate Lokelma access management into your daily workflow:

• Create a "specialty drug access" protocol in your EHR or office manual that includes Lokelma-specific steps (preferred pharmacies, PA documentation checklist, manufacturer program enrollment)
• Designate a staff member to handle specialty drug PA submissions and manufacturer program enrollments — this frees up provider time and ensures follow-through
• Bookmark Medfinder for Providers for quick pharmacy stock lookups during patient visits
• Keep manufacturer copay cards in the office to hand to patients at the point of prescribing
• Track PA outcomes — if you're seeing high denial rates for Lokelma, it may be worth a peer-to-peer review or appeal to establish coverage precedent with specific payers

Final Thoughts

Lokelma access challenges are solvable — they just require proactive coordination between your office, the pharmacy, the payer, and the patient. By building Lokelma access strategies into your prescribing workflow, you can reduce the burden on patients and ensure consistent potassium management.

The tools exist: Medfinder for Providers for pharmacy stock, My Access 360 for insurance and financial support, and the clinical alternatives to fall back on when needed. The key is using them systematically rather than reactively.

For the companion patient resource, share our guide on how to find Lokelma in stock near you.